What are non-drowsy allergy medications that do not cause QT (QT interval) prolongation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Fexofenadine (Allegra) is the preferred non-drowsy allergy medication that does not cause QT interval prolongation, with a typical adult dose of 180mg once daily. Several non-drowsy allergy medications that don't typically cause QT prolongation include loratadine (Claritin), cetirizine (Zyrtec), and desloratadine (Clarinex) 1. These second-generation antihistamines are generally considered safe for people concerned about QT interval prolongation. According to the guidelines for evaluation and management of urticaria in adults and children, cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine, and mizolastine are licensed for urticaria in the U.K. 1. However, mizolastine is contraindicated in clinically significant cardiac disease and when there is prolongation of the Q-T interval, making it an unsuitable option for patients with QT prolongation concerns 1.

Key Considerations

  • Fexofenadine has the least potential for cardiac effects and minimal sedation, making it a preferred option 1.
  • The typical adult dose is 180mg once daily for fexofenadine, 10mg once daily for loratadine and cetirizine, and 5mg once daily for desloratadine.
  • These medications work by blocking histamine receptors without significantly crossing the blood-brain barrier, which is why they cause less drowsiness than older antihistamines.
  • It's essential to note that while these medications are generally considered safe regarding QT prolongation, anyone with heart conditions or taking other medications should consult with their healthcare provider before starting any new medication, as individual factors and drug interactions can affect safety 1.

Important Safety Information

  • Patients with renal impairment should avoid certain medications, such as acrivastine, which should be avoided in moderate renal impairment (creatinine clearance 10–20 mL min) 1.
  • Patients should be offered the choice of at least two nonsedating H1 antihistamines because responses and tolerance vary between individuals 1.

From the FDA Drug Label

No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole The non-drowsy allergy medication fexofenadine does not cause QT interval prolongation, as indicated by the lack of differences in QTc interval observed in studies 2.

  • Key points:
    • Fexofenadine hydrochloride was administered alone or in combination with erythromycin or ketoconazole
    • No differences in QTc interval were observed
    • Fexofenadine is a non-drowsy allergy medication
    • The medication is prescribed for the relief of symptoms of seasonal allergic rhinitis or chronic idiopathic urticaria (hives)

From the Research

Non-Drowsy Allergy Medications

Non-drowsy allergy medications that do not cause QT interval prolongation include:

  • Loratadine 3, 4, 5, 6
  • Cetirizine 3, 4, 5, 6
  • Fexofenadine 3, 4, 5, 7
  • Desloratadine 5, 7, 6
  • Levocetirizine 7, 6
  • Bilastine 7
  • Rupatadine 7

Mechanism of QT Interval Prolongation

The cardiotoxic effects of some nonsedating antihistamines are due to the inhibition of repolarization potassium channels, particularly IKr, which leads to prolongation of the action potential and QT interval, and the development of early after-depolarization, which triggers torsades de pointes (TdP) 3.

Safety Considerations

Patients at risk of developing TdP, such as those with congenital long QT syndrome, cardiac disease, liver disease, electrolyte disturbance, or those taking drugs that can prolong QT interval, should avoid nonsedating antihistamines that are also capable of prolonging the QT interval 3, 7. Caution is needed when using loratadine in patients with risk factors for torsades de pointes or who are taking certain enzyme inhibitors 6. Cetirizine should be avoided in cases of renal failure 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Potential cardiac toxicity of H1-antihistamines.

Clinical allergy and immunology, 2002

Research

Pharmacokinetic overview of oral second-generation H1 antihistamines.

International journal of clinical pharmacology and therapeutics, 1998

Research

Present and potential therapy for allergic rhinitis: a review.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2000

Research

Cardiac safety of second-generation H1 -antihistamines when updosed in chronic spontaneous urticaria.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.